Medical Doctor Program year 2025 Reported 2022–2025 Source: CMS Open Payments, 2026 publication

Amanda Woodward

Hospice and Palliative Medicine Lincoln, NE Medical Doctor

NPI 1013464114 CMS profile 1991240

4004 Pioneer Woods Dr, Lincoln, NE 68506

Open in the dashboard

General payments

$651

23 records reported · program years 2022–2025

Research payments

$0

Paid to them · None reported · program years 2022–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Amanda Woodward of Lincoln, NE is reported in the CMS Open Payments database as having received $651 across 23 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 84th percentile of Hospice and Palliative Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $143 7
2024 General $331 6
2023 General $153 9
2022 General $24 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Amanda Woodward
  • Hospice and Palliative Medicine median
  • Middle half of Hospice and Palliative Medicine
  • National median

In program year 2025, general payments to Amanda Woodward were reported at $143. Among 151 Hospice and Palliative Medicine profiles paid that year, the median was $79 and the middle half received between $28 and $179.

Show as a table
Year Amanda Woodward Hospice and Palliative Medicine median Middle half National median
2019 $0 $70 $20–$164 $163
2020 $0 $67 $19–$171 $114
2021 $0 $81 $22–$170 $132
2022 $24 $92 $29–$229 $149
2023 $153 $98 $33–$185 $160
2024 $331 $68 $24–$170 $164
2025 $143 $79 $28–$179 $169

Breakdown

Who paid General payments · program years 2022–2025
  1. Aimmune Therapeutics, Inc. $239 1 payment
  2. Janssen Biotech, Inc. $47 2 payments
  3. Novartis Pharmaceuticals Corporation $37 2 payments
  4. Eisai Inc. $33 2 payments
  5. Iovance Biotherapeutics, Inc. $25 1 payment
  6. EMD Serono, Inc. $21 1 payment
  7. Sobi, Inc $21 1 payment
  8. Merck Sharp & Dohme Corporation $21 1 payment
  9. AstraZeneca Pharmaceuticals LP $21 1 payment
  10. Vertex Pharmaceuticals Incorporated $20 1 payment
  11. Other $165 10 payments

Every payment, record by record

What the payments were for General payments · program years 2022–2025
  1. Food and Beverage $651 23 payments
Products named General payments · program years 2022–2025
  1. ZENPEP $239 1 payment
  2. Lenvima $33 2 payments
  3. Amtagvi $25 1 payment
  4. DARZALEX $24 1 payment
  5. IMBRUVICA $24 1 payment
  6. RYBREVANT $23 1 payment
  7. VONJO $21 1 payment
  8. KEYTRUDA $21 1 payment
  9. TAGRISSO $21 1 payment
  10. TIVDAK $20 1 payment
  11. Other $259 16 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 23 drugs

Part D claims

666

Median for Hospice and Palliative Care: 260

Drug cost

$40,015

Median for Hospice and Palliative Care: $10,445

Branded share of claims

23.3%

Median for Hospice and Palliative Care: 16.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Xarelto Rivaroxaban Brand 18 $12,273
Movantik Naloxegol Oxalate Brand 17 $6,688
Buprenorphine Generic 31 $5,921
Fentanyl Generic 51 $4,073
Duloxetine Hcl Generic 36 $1,811
Pregabalin Generic 36 $1,796
Morphine Sulfate Er Morphine Sulfate Brand 45 $1,364
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 46 $1,191
Gabapentin Generic 86 $945
Olanzapine Generic 36 $800

The 10 drugs with the highest cost, of 23 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 1,124 Part D prescribers listed as Hospice and Palliative Care; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 60 billing codes

Paid by Medicare

$485,581

Of which drugs: $426,490

Medicare patients

258

Average age 74

Services billed

45,044

140 women, 118 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Cancer 59%
Arthritis 53%
Chronic kidney disease 35%
Depression 35%
Ischemic heart disease 33%
Diabetes 29%
COPD 28%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, pegfilgrastim-pbbk (fylnetra), biosimilar, 0.5 mg Q5130 Office 45 1,788 $274,826
Infusion, normal saline solution , 1000 cc J7030 Office 45 285 $548
Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg J3420 Office 45 178 $161
Injection, dexamethasone sodium phosphate, 1 mg J1100 Office 17 600 $55
Injection, potassium chloride, per 2 meq J3480 Office 13 255 $22

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

5 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
ZENPEP
  • AIMMUNE THERAPEUTICS, INC. $239
$239 — —
VONJO
  • Sobi, Inc $21
$21 — —
Empaveli
  • Apellis Pharmaceuticals, Inc. $17
$17 — —
Lenvima
  • Eisai Inc. $17
$17 — —
SARCLISA
  • GENZYME CORPORATION $15
$15 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

23 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record